The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease

BÜHLMANN fCAL® ELISA Citation

Zhulina, Y. et al., 2016, The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease, Aliment Pharmacol Ther.  PMID: 27402063 DOI: 10.1111/apt.13731

Highlight from this Publication

“Our data suggest that longitudinal monitoring of faecal calprotectin is informative in predicting relapse in IBD.“

Read Citation

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use.

Health Canada License: 80726

This citation describes applications that are outside of product claims (Intended use is: The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.) thus this “non-diagnosis” citations should be used for information only.